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Purpose: There is a lack of standards for the diagnosis, assessment and management of
breakthrough cancer pain (BTcP). La Fundación ECO (the Foundation for Excellence and
Quality in Oncology) commissioned a study to establish a consensus and lay the foundations
for the appropriate management of BTcP in oncology patients.
Patients and methods: A modified Delphi survey comprising two rounds was used to
gather and analyze data, which was conducted over the Internet. Each statement that reached
a consensus with the respondents was defined as a median consensus score (MED) of ≥7, and
agreement among panelists as an interquartile range (IQR) of ≤3.
Results: In total, 69 medical oncologists responded, with a broad consensus that BTcP implied
exacerbations of high-intensity pain, as opposed to moderate pain. Furthermore, they concurred
that appropriate diagnostic equipment is needed, and that rapid-onset fentanyl formulations
should be the preferred treatment for BTcP management. The panelists agreed that a lack of
appropriate information and training to attend to patients, as well as limited patient visitation
rights, were barriers to effective BTcP management. Regarding gaps in detected knowledge,
the panelists were unsure of the measures necessary to assess the burden of the disease on the
patient’s quality of life and associated medication costs. Alongside this, there was a lack of
awareness of the technical specifics of the different formulations of rapid-onset fentanyl.
Conclusion: These results represent the current status of BTcP management. They may
inform recommendations and provide a framework for future research.
Keywords: breakthrough pain, rapid-onset opioids, fentanyl, medical oncology, pain
management
Introduction
Breakthrough cancer pain (BTcP) management is one of the most challenging
problems associated with cancer pain, and has been linked to a negative impact
on the patient’s quality of life (QoL) and ability to function. It can lead to higher
levels of depression and anxiety, poorer prognostic on future pain relief, and an
increased burden for families and health services.1–6
The prevalence of BTcP has been reported to range from 19% to 95%, depend-
ing on the BTP definition and the clinical setting.1,3,5,7 The International
Association for the Study of Pain (IASP) estimates that between one half and two
thirds of patients with chronic cancer-related pain experience BTcP episodes.
Despite its prevalence, BTcP remains an underdiagnosed and undertreated
condition. The reasons for this are probably multifactorial, resulting from a lack
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of official definition, and unjustified attitudes and miscon-
ceptions held by healthcare professionals and patients
regarding opioids.5,9–12
Despite international efforts, there is still no one uni-
versally accepted BTcP definition.13,14 Overall, BTcP can
be considered as a relevant transitory increase in pain.
However, there is controversy regarding the intensity of
this pain and the patient’s basal pain (absence of BTcP,
BTcP effectively treated with opioids or uncontrolled
BTcP).15–17
Notwithstanding the proliferation of guidelines addres-
sing pain in cancer patients,6–8,18,19 there is no consensus
on BTcP management, and recommendations are hetero-
genous, which is preventing the establishment of an ade-
quately analgesic approach.
Classically, treatment options involve the optimization
of the scheduled background analgesia and supplementing
it with “rescue” medication when BTcP occurs.18 Short-
acting opioids (SAOs) — immediate-release formulations
of morphine—were previously considered the standard of
care. However, recent evidence shows that rapid-onset
opioids (ROOs) provide safe and effective BTcP manage-
ment. ROO formulations are characterized by a rapid onset
and short duration of action, consistent with the nature of
BTcP episodes (acute)7,14,17,20 and the rapid resolution of
pain required by these patients.15
The pharmacokinetics and tolerability profile of rapid-
acting fentanyl products render them suitable for mana-
ging the acute, severe pain intensity that generally char-
acterizes BTcP episodes.19,21,22
Additionally, individualized therapy is made further
possible due to the wide range of different rapid-onset
fentanyl formulations and preparations available.
However, the absence of comprehensive comparative trials
means physicians must rely on their understanding and
experience when prescribing the medication. This is
important to determine the most effective and best-toler-
ated formulations for each patient.16,17,20
In light of the above, physicians should be aware that
rapid-onset fentanyl formulations are not bioequivalent (as
they have substantial practical differences); nor are they
interchangeable. Each formulation will have a different
type of titration, depending on the needs of the patient.17
In clinical practice, the successful management of
BTcP requires careful assessment, ongoing reassessment,
and a treatment that is tailored to the individual patient.
The treatment should also consider the type and cause of
the BTcP, as well as patient preferences.6,23
Within this context, the Foundation for Excellence and
Quality in Oncology (ECO) commissioned a study to
establish a consensus. This could subsequently be used to
lay the foundations for the appropriate management of
BTP (severely intense pain) in cancer patients. The goal
of the study was to achieve a consensus among medical
oncologists on a clinical approach towards the diagnostic
evaluation and appropriate pharmacological management
of patients with BTcP, specifically with rapid-onset fenta-
nyl formulations.
Materials and methods
This study was carried out gathering and analyzing the
opinion of expert using the Delphi method. In Spain this
type of study is not included among those requiring
Research Ethics Committees (RECs) approval or written
consent.
A Scientific Committee (SC) was appointed, compris-
ing three members from the Foundation for Excellence and
Quality in Oncology and two support methodologists. The
SC developed the questions for the first round, structured
the questionnaire, set up the online questionnaire into the
website created to the study, undertook statistical analysis
of the data, produced interim documents and oversaw the
process’s general management.
The expert panel members, selected by the SC,
included 71 Spanish oncology experts who were invited
to participate in the consensus process through a modified
Internet-based Delphi survey made up of two rounds.
Experts were identified from a selection of physicians
specializing in medical oncology, and each possessed
documented clinical expertise in cancer management at
referral hospitals. The Delphi participants were located in
geographically diverse parts of Spain, and were sent an
email inviting them to take part in the study, as well as a
link to access the questionnaire on the survey website.
The questionnaire
A selection of 50 statements were developed, each of
which was relevant to the diagnosis, assessment and man-
agement of BTcP, and based on controversies found in
both clinical practice and existing literature.15,24–26 The
questionnaire was administered in Spanish. The purpose
was to reach a consensus on questions arising from: a) The
definition and assessment of BTcP; b) The therapeutic
approach to BTcP; and c) The clinical rationale for admin-
istering fentanyl ROOs for BTcP treatment.
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There was a further text-based question that allowed
the experts to provide a figure for the prevalence of BTcP,
as informed by their own clinical practice.
Finally, we asked 10 closed-ended questions about any
perceived differences between the different systems or
routes to administer fentanyl ROOs and the preferences
of participants.
Panelists were asked to indicate their level of agreement
with each statement using a nine-point Likert scale (one
being “strongly disagree,” nine being “strongly agree”).
Free text space was also provided to encourage comments.
Consensus definition and data analysis
The median response (MED) and interquartile range (IQR)
were calculated for each statement. The level of agreement
required for consensus among the panel members was
decided prior to commencing the study.
Each statement that reached a consensus with the respon-
dents was defined as a median consensus score (MED) of ≥7,
and agreement among panelists as an interquartile range
(IQR) of ≤3. Similarly, a MED score of ≤3 was considered
to represent a consensus to reject the statement.
An IQR of ≥4 required a review of the criteria by the
SC (via discussion). The statements in question were then
either revised and included in the second questionnaire, or
rejected based on additional comments received from
panel members.
The questionnaire used in the second round contained
the previous median and IQR of the ratings obtained in the
first round for each retested statement, as well as some
comments to clarify the wording. Respondents were asked
to re-rate each item, using the information from the pre-
vious round as feedback, and to comment upon their rat-
ing. After the second round, the revised MED and IQR
values were calculated.
Results
The participants were made up of expert oncologists from
14 of Spain’s 17 Autonomous Communities. In the first
round, 69 out of the 71 identified experts (97.2%)
responded (male, n=29; 42%). Of the 69 questionnaires
received, 66 were complete, two had two missing items
and one had three missing items. All 69 respondents who
took part in the first round also responded to the second
one with a 100% compliance rate (no missing items).
Response rates are shown in Figure 1. The statements
provided for consideration and subsequent consensus
among participants are shown in Table 1.
Definition and assessment of BTcP
Regarding the definition of BTcP, the experts strongly
agreed upon it being an “Acute exacerbation of high-
intensity pain of short duration and rapid onset, suffered
by a patient whose baseline pain is stabilized and con-
trolled by opioids” (MED=9, IQR=1). In contrast, the
statement defining BTcP as “moderate” failed to reach an
acceptable level of agreement after the second round
(MED=7, IQR=5).
When rating the characteristics and assessment criteria
for BTcP diagnosis, experts reached acceptable consensus
scores after the second round on the majority of criteria.
The statement “diagnosis of BTcP requires more than four
daily episodes” failed to confirm a consensus, but did
reach quite a high level of agreement (IQR=2.5).
Qualitative comments made by the experts reflected the
idea that establishing a minimum number of episodes
could not help to define whether a patient was suffering
from BTcP, and that an isolated episode could be diag-
nosed and managed as BTcP. Interestingly, in the first
round, the statement “Validated pain assessment tools
should be used in diagnosing BTcP” reached quite a high
consensus score among the experts (MED =7, IQR=3). In
the second round, the item was slightly changed to
“Medical judgment in diagnosing BTcP prevails over vali-
dated scales”, which improved agreement levels (IQR=0).
The statement “A maximum of nine episodes per day
demonstrates a poor treatment of BTcP” was rejected
(MED=2, IQR=2). This was done on the grounds that
over four episodes a day should be considered a case of
poor baseline pain analgesia rather than BTcP. There was
no consensus on the statement “Patients are reluctant to
report pain due to fear of treatment” (MED=5, IQR=4).
The item regarding the assessment of QoL failed to reach a
consensus (MED=5, IQR=4) and the item on the avail-
ability of tools to educate patients (MED=3, IQR=2)
reached a negative consensus, indicating disagreement.
Qualitative comments agreed that such statements were
justified, but emphasized that they did not reflect daily
clinical practice.
Therapeutic approach in BTcP
After the second round, a high level of consensus and an
acceptable level of agreement were obtained in regard to
almost all of the statements. Particularly the following
statements: “potent, rapid-onset opioids should be used to
treat BTcP” (MED=9, IQR=1); “rapid-onset fentanyl is the
Dovepress Camps Herrero et al
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treatment of choice for most patients suffering from BTcP”
(MED=8, IQR=2); “the strategy of using the same opioid,
although in different formulations for baseline pain and
BTcP, is not necessary” (MED=8, IQR=1); and “incidental
BTcP related to a predictable trigger factor can be treated
with different fentanyl formulations, taking the patient’s
preference into account” (MED=8, IQR=2).
Panelists rejected the use of weak opioids (WHO step II
analgesics) as the treatment of choice for BTcP (MED=8,
IQR=2), as well as the use of immediate-release oral
opioids due to their slow onset of action (MED=7, IQR=3).
Clinical rationale for administering rapid-
onset fentanyl opioids for BTcP
After the first round, items relating to cost-effectiveness
were removed from the questionnaire after panelists
expressed their unfamiliarity with medication costs. Even
so, they reached a consensus, and arrived at an adequate
level of agreement, in terms of taking costs into account
when choosing a formulation for BTcP management
(MED=7, IQR=0). There was widespread consensus that
clinical practice implies knowing the pharmacokinetic pro-
file of the different fentanyl formulations (MED=8,
IQR=2). Consequently, statements suggesting the bioequi-
valence or therapeutic equivalence with regard to prescrib-
ing the different formulations were ultimately rejected.
Patients should play an increasingly active role in thera-
peutic choices (MED=9, IQR=1).
The survey which researched the preferred route of
administration revealed a marked bias towards sublingual
administration in terms of patient and clinician prefer-
ences, usability in different care settings, and ease of
administration for physically disabled patients. The intra-
nasal administrative route was considered to provide a
faster onset of action, and to be more suitable for patients
suffering mucositis. Oral transmucosal delivery scored the
lowest across all items. Table 2.
Lastly, the open-ended question revealed a high con-
sensus and total agreement with regard to the prevalence
of BTP in cancer patients (MED=7; IQR=0). The figures,
Fundación eco-scientific committee
•Screening and recruitment of medical oncology experts
•Development of the web-based questionnaire
71 medical oncologist invited to participate in the panel
First phase: delphi survey sent to 71 panelists
69 responders (Response rate: 69/71, 97.2%)
Analysis of first round outcomes
Second phase: rerate each statement using summary of responses from the previous round as 
feedback and comment upon 
Second phase: delphi survey sent to 69 panelists
69 responders (Response rate: 69/69; 100%)
Final results
Consensus
•Correct use of BTcP definition
•Appropriate tools to diagnose
•Fentanyl ROOs treatment of 
choice for BTcP management
Barriers
•More time for visits
•Patient’s training and education
•Patient’s information material 
Gaps
•Patient’s quality of life 
assessment
•Technical knowledge of different 
fentanyl ROOs
•Information on cost
Key: BTcP: Breakthrough cancer pain; ROOs: Rapid Onset Opioids
Figure 1 Flowchart of participants in the study.
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stated by the experts, ranged from 20–80%. Interestingly,
one expert provided a figure of 100% for both lung and
genitourinary cancers.
Discussion
The purpose of this study was to reach a consensus that
would lay the foundations for the appropriate management
of BTP in cancer patients. The first step of clinical diagnosis
is to discuss the pain. Therefore, the physician should make
sure to ask the patient explicitly about pain flares until a
diagnosis of BTcP can be confirmed.27 There was a differ-
ence of opinion among respondents concerning the definition
of BTcP. Most experts agreed that the qualifier “high” should
be included in the definition, but rejected “moderate;” this is
in line with the well-illustrated controversy present in med-
ical literature.11,12,22 Therefore, this result demonstrates that
BTcP implies a severe pain, in terms of intensity levels.
According to the experts, diagnosing BTcP depends on
the presence of well-controlled background pain, which
means that the development and progression of BTcP may
also represent problems related to undertreated baseline
pain. The guidelines consider that “adequate control of
baseline pain” is an essential prerequisite to begin specific
treatment for BTcP. However, no clear definition exists in
scientific literature.15 In clinical practice, analgesic therapy
for BTcP should be based on integration into the back-
ground pain’s therapeutic strategy. However, it is not always
easy to distinguish BTcP from variations in the outcome
assessment of baseline pain (for instance, end-of-dose pain).
A recent study found that where patients had back-
ground pain of ≤4/10 on a numerical scale, the mean-
ingful pain intensity at which they asked for BTcP
medication was approximately 7/10.28 The experts par-
ticipating in the present study agreed that ≤3/10 on a
VAS scale means “controlled,” implying very mild
background pain. Consequently, >5/10 means “moder-
ate” pain, and it is from this point on the scale that
BTcP should be assessed.
Regarding the statements on the use of opioids in
managing BTcP, oncologists showed a great amount of
knowledge. The SEOM (Spanish Society for Medical
Oncology) recommendations29 and ESMO30 and EAPC
guidelines8 state that ROOs should be considered first-
line treatment for BTcP. In 2008, a survey conducted in
Spain reported that fentanyl was largely the opioid most
commonly used for treating cancer pain.31 Indeed, clini-
cians showed appropriate knowledge in the safe and effec-


























































































































































































































































































































































































































































































































































Dovepress Camps Herrero et al

































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1
they scored poorly when asked about specific clinical
scenarios and their scientific and technical knowledge
regarding the different systems and routes of administra-
tion. These gaps in their knowledge concur with the find-
ings of previous studies conducted in the USA and Asia,
indicating that oncologists may not fully realize these
weaknesses in their knowledge.32,33
Experts also highlighted a noteworthy concern: limited
attention is paid to QoL, despite its importance in patient
well-being. In line with this, a recent pan-European survey
found that adult oncology patients expressed that physi-
cians were not interested in their QoL.5 Similarly, 52% of
patients surveyed by the American Pain Foundation
reported that they were told BTcP was a normal side effect
of cancer and/or its treatment.34 In this context, the present
study identified a need to disseminate information and
raise awareness among medical oncologists about the bur-
den of BTcP on QoL. With that in mind, they can carry out
their role correctly when dealing with this condition.
As for barriers to managing BTcP, experts denied that
patients were reluctant to report pain. They did emphasize,
however, the absence of clear, appropriate information avail-
able to patients, as well as the limited amount of time they had
in clinical practice to discuss pain and educate them about pain
management. These results are similar to those reported in
different surveys from all around the world,32,33,35 in which
time limitations and patient training were identified as signifi-
cant barriers to the effective management of BTcP. Thus, it is
apparent that there is a need for the development of patient
information resources that provide clear and simple instruc-
tions, as education and patient compliance have been identified
as the most important factors in appropriately managing pain.2
While there was a strong consensus that “Specific atten-
tion should be paid to cost when choosing a fast-acting
fentanyl formulation for BTcP management” (MED=7;
IQR=0), it should be noted that questions about cost were
withdrawn in the second round due to qualitative comments
reporting a lack of knowledge about prices. This finding
concurs with the lack of cost-effectiveness analyses on
BTcP treatments36 and oral fentanyl formulations, as recently
stated by Italian clinicians.37 Doctors who prescribe these
medications are aware of the substantial difference in cost
between fentanyl formulations and immediate-release mor-
phine or oxycodone,38 but cost-effectiveness analyses are
needed in order to help them to select the best formulation.37
In BTcP treatment, rapid onset of action and ease of
use are universal variables in the prescription process
across all care settings. That being said, we should note
that the characteristics of BTcP, the preferences of the
patient, and the therapeutic setting may influence their
first therapeutic choice. A possible change in therapeutic
choice and the route of administration should also be taken
into consideration.
Although comparison studies among different fentanyl
formulations are lacking, results from different studies
showed that the sublingual route is well accepted by
patients in terms of ease and modality of administration,
mucoadhesivity, and their overall satisfaction,39,40 which is
in line with the preferences reported in our study. Intranasal
administration seems promising, but involves the mandatory
use of specific delivery devices which affects usability.41
The oral transmucosal route of administration received a
lower score for modality of administration and the time
taken to achieve pain relief; furthermore, this approach
requires experienced patients.16,17
In short, oncologists must be aware of the particular
features of each medication, such as the different pharma-
cokinetics, titration specifics, dosing intervals, and the
Table 2 Indications, contraindications and pharmacokinetics of the different routes of administration of rapid onset fentanyl
Intranasal Oral transmucosal Sublingual
Preferred by patients √ √ √√√
Suitable for impaired patients √ X √√√
Patients with mucositis √√√ √ √√
Patients with diabetes √√√ X √√
Preferred by clinicians √ √ √√√
Usability in any care setting √√ √ √√√
Reduced dosing interval √√√ √ √√
Faster absorption √√√ √ √√
Easiness for titration √√ √ √√√
Widest range of forms and strengths X √ √√√
Notes: √√√= (MED=≥8, IQR=≤1); √√= (MED=7; IQR=2–3) √= (MED=7; IQR=≥4); X= no consensus.
Camps Herrero et al Dovepress
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technical characteristics of its accessibility and delivery, as
well as possible limitations in everyday clinical practice.
According to our Delphi survey (items with or without
consensus), there are apparent knowledge gaps to be filled.
Therefore, our results will need to be taken into considera-
tion when planning future trial analyses on fentanyl for-
mulations, so as to extract all the necessary information to
answer unresolved questions about its use; new trials must
be also developed.
Furthermore, the needs identified, regarding the assessment
and treatment of BTcP and the lack of awareness surrounding
its impact on patients’ QoL, could be used to devise and
disseminate useful indications and recommendations (which
could then be included in training programs for oncologists).
The limitations of this study include its declared focus
on opioids, which has led to a lack of results in terms of
the final consensus concerning the integration of other
treatment strategies and methods. Moreover, this survey
was devised to develop and evaluate a consensus to spe-
cifically address severe BTP that results from cancer or
cancer treatment. It is therefore possible that if an alter-
native approach were used, different criteria would be
needed to carry out the study.
Finally, the consensus, based on expert opinion, repre-
sents a low level of evidence with potential for bias, and
thus may not be entirely accurate. Although we selected our
panel using an empirical approach based on clinical exper-
tise, we must consider the possibility of collecting more
diverse responses if we had a different selection of respon-
dents as palliative care physicians or anaesthesiologists.
Conclusion
These findings represent a pragmatic approach to the diag-
nosis and pharmacological management of severe BTcP.
The documented consensus can act as a useful tool to
analyze current clinical practice. It also provides a frame-
work for properly inquiring about RCTs and for evaluating
the efficiency and safety of the various ROOs formulations.
This consensus does not include specific treatment
recommendations. This is due to the currently established
rule of adjusting the dosage and route of administration
according to the individual needs of each patient: indivi-
dualization of BTcP opioid therapy is key to implementing
the most effective treatment.
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